101 Grants (Page 1 of 5)
2021
Contribution of Osteocytes to the Musculoskeletal Effects of Multiple Myeloma
BELLIDO, TERESITA M and ROODMAN, GARSON D
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA209882-06), $409,850USD, 2017-03-15 -- 2022-02-28
 
Manipulating the N-end Rule Protein Degradation Pathway to Build Bone and Decrease Tumor Growth in Multiple Myeloma Bone Disease
ROODMAN, GARSON D
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA241677-02), $332,471USD, 2020-03-04 -- 2025-02-28
2020
Contribution of Osteocytes to the Musculoskeletal Effects of Multiple Myeloma
BELLIDO, TERESITA M and ROODMAN, GARSON D
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA209882-04), $424,680USD, 2017-03-15 -- 2022-02-28
 
Contribution of Osteocytes to the Musculoskeletal Effects of Multiple Myeloma
BELLIDO, TERESITA M and ROODMAN, GARSON D
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 7R01CA209882-05), $349,622USD, 2017-03-15 -- 2022-02-28
 
Manipulating the N-end Rule Protein Degradation Pathway to Build Bone and Decrease Tumor Growth in Multiple Myeloma Bone Disease
ROODMAN, GARSON D
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R01CA241677-01A1), $332,471USD, 2020-03-04 -- 2025-02-28
2019
Contribution of Osteocytes to the Musculoskeletal Effects of Multiple Myeloma
Bellido, Teresita M and ROODMAN, GARSON D
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA209882-03), $411,939USD, 03/15/2017 -- 02/28/2022
 
Role of Gfi-1 in Myeloma Bone Disease
ROODMAN, GARSON D
National Institutes of Health (NIH), Veterans Affairs (VA) (ID: 5I01CX000623-08), 07/01/2012 -- 06/30/2020
2018
Contribution of Osteocytes to the Musculoskeletal Effects of Multiple Myeloma
Bellido, Teresita M and ROODMAN, GARSON D
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA209882-02), $363,594USD, 03/15/2017 -- 02/28/2022
 
MVNP, p62P392L and IL-6 in the Pathogenesis of PD
ROODMAN, GARSON D
National Institutes of Health (NIH), National Institute of Arthritis and Muscoloskeletal and Skin Diseases (NIAMS) (ID: 5R01AR057308-11), $380,064USD, 09/15/2008 -- 04/30/2019
 
Role of Gfi-1 in Myeloma Bone Disease
ROODMAN, GARSON D
National Institutes of Health (NIH), Veterans Affairs (VA) (ID: 5I01CX000623-07), 07/01/2012 -- 06/30/2020
2017
Cancer and Bone Society (CABS) Meeting 2017
ROODMAN, GARSON D
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R13CA217090-01), $2,250USD, 04/14/2017 -- 03/31/2018
 
Contribution of Osteocytes to the Musculoskeletal Effects of Multiple Myeloma
Bellido, Teresita M and ROODMAN, GARSON D
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R01CA209882-01A1), $402,712USD, 03/15/2017 -- 02/28/2022
 
MVNP, p62P392L and IL-6 in the Pathogenesis of PD
ROODMAN, GARSON D
National Institutes of Health (NIH), National Institute of Arthritis and Muscoloskeletal and Skin Diseases (NIAMS) (ID: 5R01AR057308-10), $342,057USD, 09/15/2008 -- 04/30/2019
 
Role of Gfi-1 in Myeloma Bone Disease
ROODMAN, GARSON D
National Institutes of Health (NIH), Veterans Affairs (VA) (ID: 5I01CX000623-06), 07/01/2012 -- 06/30/2020
2016
MVNP, p62P392L and IL-6 in the Pathogenesis of PD
ROODMAN, GARSON D
National Institutes of Health (NIH), National Institute of Arthritis and Muscoloskeletal and Skn Diseases (NIAMS) (ID: 5R01AR057308-09), $380,305USD, 09/15/2008 -- 04/30/2019
 
Role of Gfi-1 in Myeloma Bone Disease
ROODMAN, GARSON D
National Institutes of Health (NIH), Veterans Affairs (VA) (ID: 2I01CX000623-05), 07/01/2012 -- 06/30/2020
2015
MVNP, p62P392L and IL-6 in the Pathogenesis of PD
ROODMAN, GARSON D
National Institutes of Health (NIH), National Institute of Arthritis and Muscoloskeletal and Skn Diseases (NIAMS) (ID: 5R01AR057308-08), $393,822USD, 09/15/2008 -- 04/30/2019
 
Role of Microenvironmental-Derived AXII in Myeloma Bone Disease
ROODMAN, GARSON D
National Institutes of Health (NIH), Veterans Affairs (VA) (ID: 5I01CX000623-04), 07/01/2012 -- 06/30/2016
2014
GFI-1 and Osteoblast Suppression in Multiple Myeloma
Galson, Deborah L and ROODMAN, GARSON D
National Institutes of Health (NIH), National Institute of Arthritis and Muscoloskeletal and Skin Diseases (NIAMS) (ID: 5R01AR059679-05), $272,051USD, 07/26/2010 -- 12/31/2015
 
Hypersensitivity of Multiple Myeloma Bone Disease to Vitamin D
ROODMAN, GARSON D
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R21CA179017-02), $197,473USD, 07/19/2013 -- 06/30/2015
 
MVNP, p62P392L and IL-6 in the Pathogenesis of PD
ROODMAN, GARSON D
National Institutes of Health (NIH), National Institute of Arthritis and Muscoloskeletal and Skn Diseases (NIAMS) (ID: 2R01AR057308-07A1), $369,495USD, 09/15/2008 -- 04/30/2019
 
Role of Microenvironmental-Derived AXII in Myeloma Bone Disease
ROODMAN, GARSON D
National Institutes of Health (NIH), Veterans Affairs (VA) (ID: 5I01CX000623-03), 07/01/2012 -- 06/30/2016
2013
GFI-1 and Osteoblast Suppression in Multiple Myeloma
Galson, Deborah L and ROODMAN, GARSON D
National Institutes of Health (NIH), National Institute of Arthritis and Muscoloskeletal and Skin Diseases (NIAMS) (ID: 5R01AR059679-04), $263,723USD, 07/26/2010 -- 06/30/2015
 
Hypersensitivity of Multiple Myeloma Bone Disease to Vitamin D
ROODMAN, GARSON D
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R21CA179017-01), $169,650USD, 07/19/2013 -- 06/30/2015
 
Role of Microenvironmental-Derived AXII in Myeloma Bone Disease
ROODMAN, GARSON D
National Institutes of Health (NIH), Veterans Affairs (VA) (ID: 7I01CX000623-02), 07/01/2012 -- 06/30/2016